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Abstract. In the yeast Saccharomyces cerevisiae, 
Secl3p is required for intracellular protein transport 
from the ER to the Golgi apparatus,  and has also been 
identified as a component of the COPII vesicle coat 
structure.  Recently, a human cDNA encoding a pro- 
tein 53%  identical to yeast Secl3p has been isolated. 
In this report,  we apply the genetic assays of com- 
plementation and synthetic lethality to demonstrate the 
conservation of function between this human protein, 
designated SEC13Rp, and yeast Secl3p. We show that 
two reciprocal human/yeast fusion constructs, encod- 
ing the NH2-terminal half of one protein and the 
COOH-terminal half of the other,  can each comple- 
ment the secretion defect of a sec13-1 mutant at 36°C. 
The chimera encoding the NH2-terminal half of the 
yeast protein and the COOH-terminal half of the hu- 
man protein is also able to complement a SEC13 dele- 
tion.  Overexpression of either the entire human 
SEC13Rp protein or the chimera encoding the NH2- 
terminal half of the human protein and the COOH- 
terminal half of the yeast protein inhibits the growth 
of a sec13-1 mutant at 24°C;  this growth inhibition  is 
not seen in a wild-type strain nor in other sec mu- 
tants,  suggesting that the NH2-terminal half of 
SEC13Rp may compete with Secl3-1p for a common 
target.  We show by immunoelectronmicroscopy of 
mammalian  cells that SEC13Rp (like the putative 
mammalian  homologues of the COPII subunits Sarlp 
and Sec23p) resides in the region of the transitional 
ER.  We also show that the distribution of SEC13Rp is 
not affected by brefeldin A treatment.  This report 
presents the first demonstration of a putative mam- 
malian COPII component functioning in yeast, and 
highlights  a potentially useful approach for the study 
of conserved mammalian proteins in a genetically trac- 
table system. 
p 
ROTEINS secreted by eukaryotic  cells are vectorially 
transported from the ER through the Golgi apparatus 
to the cell surface in a  series of steps mediated by 
membrane-bounded vesicles  (Palade,  1975). The ability to 
study vesicle budding  and fusion events in both yeast and 
mammalian  systems has greatly  facilitated the detailed mo- 
lecular study of intracellular  protein transport (Pryer et al., 
1992; Rothman and Orci,  1992; Kaiser,  1993). 
Vesicular  transport  between adjacent  Golgi  stacks has 
been extensively investigated in mammalian  systems, and a 
clear model has now emerged (Ostermann  et al.,  1993). In 
this  scheme,  transport  is  initiated  by  the  attachment  of 
the  small  molecular  weight  GTP-binding  protein,  ADP- 
ribosylation  factor  (ARF),'  to  the  donor  compartment 
(Donaldson et al., 1992; Helms and Rothman,  1992; Helms 
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et al.,  1993). Bound ARF-GTP stimulates  the recruitment 
of coatomer,  a  seven-subunit  protein  complex,  from  the 
cytosol, and budding occurs when coatomer binds (Donald- 
son et al.,  1992; Orci et al.,  1993b,c; Palmer et al.,  1993; 
Hara-Kuge  et al.,  1994).  Finally,  the hydrolysis  of ARF- 
GTP, presumably at the target membrane, results in coat dis- 
assembly, and permits  the vesicle to fuse (Tanigawa et al., 
1993; Elazar  et al.,  1994). 
Both ARF and the/S-COP subunit of coatomer have also 
been implicated  in ER to Golgi transport.  Transport  of the 
vesicular stomatitis virus glycoprotein (VSV-G) from the ER 
is  inhibited  by the overexpression  of a dominant  negative 
ARF mutant (T3 IN) in cultured cells (Dascher and Balch, 
1994).  VSV-G transport from the ER is also inhibited  by 
/3-COP-specific  antibodies  in both microinjected (Pepper- 
kok et al.,  1993) and digitonin-permeabilized  (Peter et al., 
1993) cells. These data suggest a possible role for coatomer 
in ER to Golgi transport. 
Vesicular transport from the ER to the Golgi has been ex- 
tensively studied in the yeast Saccharomyces cerevisiae, and 
more than  20 genes have been implicated  in  this  process 
(Kaiser,  1993). One of these genes,  SEC21, is homologous 
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However,  purification of S.  cerevisiae transport-competent 
vesicles synthesized in vitro has revealed a  coat complex 
containing five proteins  previously implicated in  vesicle 
formation-Secl3p, Sec23p, Sec24p, Sec31p, and Sarlp-but 
not Sec21p (Barlowe et al., 1994). Secl3p and Sec23p were 
initially identified by temperature-sensitive mutations which 
block vesicle formation at the non-permissive temperature 
(Novick et al., 1980; Kaiser and Schekman, 1990).  Sec24p 
and Sec31p were identified by the physical association with 
Sec23p and Secl3p, respectively (Hicke et al., 1992; Salama 
et al., 1993).  Sarlp was initially isolated as a suppressor of 
a mutation in the vesicle formation gene SEC12 (Nakano and 
Muramatsu, 1989).  Since none of these proteins show any 
apparent homology to subunits of the mammalian coatomer, 
the yeast coat complex has been designated COP II (Barlowe 
et al.,  1994). 
Mammalian genes showing significant sequence similarity 
to three COPII proteins have now been identified. Using de- 
generate PCR, Kuge et al. (1994) isolated two different  mam- 
malian clones encoding proteins with predicted amino acid 
sequences 61% identical to the sequence of the yeast Sarlp 
protein.  The export of VSV-G protein from the ER is in- 
hibited by overexpression of a dominant negative Sarl mu- 
tant (T39N), as well as by the incubation of semi-intact cells 
with Sail-specific antibody.  Immuno-EM analysis reveals 
that Sarl is highly enriched on vesicular carriers in the tran- 
sitional region of the ER, consistent with a  role in ER to 
Golgi transport.  A  similar distribution was  also  seen  in 
mammalian cells for Sec23p, using cross-reacting antibodies 
raised against the yeast Sec23p protein (Orci et al.,  1991). 
A mouse Sec23p homologue, encoding a product 40% iden- 
tical to Sec23p,  was recently discovered (Wadhwa  et al., 
1993); the relationship between this protein and the protein 
that cross-reacts with the anti-yeast-Sec23p antibody has not 
yet been established.  Finally, Swaroop et al.  (1994) have 
identified a  human gene, SECI3R,  that encodes a protein 
with 53% identity and 70% similarity to the amino acid se- 
quence of the yeast COPII protein Secl3p. 
The extensive genetic study of secretion provides us with 
the tools to explore the relationship between the function of 
a  yeast COPII component and the function of a  potential 
mammalian homologue.  Perhaps  the  most direct  way to 
study this relationship is to examine the behavior of the hu- 
man protein in yeast-particularly yeast bearing a mutation 
in the corresponding endogenous gene. Not only is this ap- 
proach useful in helping us understand and compare the pro- 
cess of  vesicular transport in yeast and mammalian cells, but 
evidence of interchangeability is also required for the rigor- 
ous demonstration of homology (Tugendreich et al., 1994). 
To investigate the functional relationship between the hu- 
man protein SEC13Rp and yeast Secl3p, we examined the 
effect of human SEC13R expression in mutant and wild-type 
yeast. Through the application of two different genetic cri- 
teria- complementation (Benzer,  1962) and synthetic lethal- 
ity (Dobzhansky, 1946;  Sturtevant,  1956;  Huffaker, 1987) 
-we have been able to show that SEC13R exhibits SEC13 
function, and therefore may be designated a  mammalian 
homologue of SEC13. Although SEC13R itself does not com- 
plement the temperature-sensitive yeast mutant secl3-1, two 
reciprocal  human/yeast chimeras,  encoding  the  NH2-ter- 
minal of one protein and the COOH-terminal half of the 
other, are each able to rescue the sec13-1 secretion defect at 
36°C;  one of the chimeras can also complement a SEC13 
deletion. Furthermore, overexpression of the entire mam- 
malian gene exhibited a negative effect in sec13-1 mutants 
but not in either wild-type yeast or in other sec mutants; this 
result,  an example of the genetic phenomenon of synthetic 
lethality, strongly suggests that in yeast, Secl3p and SEC13Rp 
participate in the same pathway. Together, the genetic data 
provide compelling evidence that human SEC13Rp can func- 
tion in yeast; SEC13Rp  thus represents  the first putative 
mammalian homologue of a  yeast COPII  component to 
fulfill this criteria. 
Immuno-EM analysis of pancreatic ceils using antibodies 
raised against SEC13Rp demonstrates that SEC13Rp is con- 
centrated in the transitional ER, in a distribution indistin- 
guishable from that previously observed for Sec23  in the 
same cell type (Orci et al.,  1991, 1993a).  The distribution 
of SEC13Rp is not affected by brefeldin A treatment, in con- 
trast to the result seen for coatomer (Orci et al.,  1993a). 
As a whole, our data not only support the existence of a 
mammalian COPII structure, but also emphasize the utility 
of heterologous gene expression as tool to study conserved 
proteins (Whiteway et al.,  1993;  Thukral et al.,  1993). 
Materials and Methods 
Strains, Materials, and General Methods 
Yeast  strains used in this study are CKY8 (MATc~ 1eu2-3,1t2 ura3-52), 
RHY305  (MAT~ 1eu2-3,112 ura3-52 seal3-1 Gal+),  DSYI74 (MATd 1eu2- 
3,112 ura3-52  Gal + [pRS315,  pGAL-SECI3R]), DSY223  (MAT~ secl2-4 
leu  2-3,112 ura3-52  Gal+[pRS315,  pGAL-SEC13R]),  DSY216  (MATer 
secl3-1  1eu2-3,112 ura3-52  Ga/+[pRS315,  pGAL-SECI3R]),  DSY228 
(MATa  sec16-2 1eu2-3,112  ura3-52  Ga/+[pRS315,  pGAL-SECI3R]), 
DSY232  (MATa secl7-1  1eu2-3,112  ura3-52  Gal+[pRS315,  pGAL- 
SECI3R]),  DSY236  (MATa secl8-1  1eu2-3,112 ura3-52  GaI+[pRS315, 
pGAL-SECI  3R]). 
Yeast culture, genetic manipulations, and molecular techniques were as 
described (Sambrook et al., 1989; Rose et al., 1990).  Mammalian cell ex- 
tracts  were  prepared  by  standard  methods (Harlow  and  Lane,  1988). 
Materials were obtained from Sigma Chemical Company (St. Louis, MO) 
unless stated otherwise. 
Gel  electrophoresis was performed according to  the Laemmli  SDS- 
PAGE method using 10% polyacrylamide (Laemmli,  1970).  For Western 
blotting afffinity-purified anti-SEC13Rp antibody was used at 1:10,000 dilu- 
tion.  Secondary antibody was goat anti-rabbit IgG, conjugated to HRP 
(Amersham Corp., Arlington Heights, IL), at a  1:10,000 dilution. Filter- 
bound antibodies were then detected by peroxidase-catalyzed ehemilumi-. 
nescence (ECL kit; Amersham Corp.). 
The monkey fibroblast cell line COS was grown in complete medium 
consisting of Dulbecco's modified Eagle's medium with 10%  fetal bovine 
serum, 2 mM glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin. 
The Chinese hamster ovary cell line CHO was grown in complete medium 
consisting of Ham's FI2 medium with 5 % fetal bovine serum, 2 mM gluta- 
mine,  100  U/ml penicillin, and  100  U/mi streptomycin. Both cells lines 
were maintained at 37°C in a 5% CO2 cell incubator. 
Generation of Chimeric Constructs 
The cloning of the SECI3R gene has been previously described (Swaroop 
et al.,  1994).  A ClaI site was introduced at nucleotide 449 in the SECI3R 
cDNA, corresponding to the ClaI site present in SECI3 at nucleotide 488 
(Pryer et al., 1993), using the oligonucleotide-direeted  mutagenesis method 
of Kunkel et al. (1987).  The (antisense) primer used for this mutagenesis 
was: 5"GGCAATGGTGTGAGCATCGA__TGATCTTCTTTACTTC-3'; altered 
nucleotides are underlined. In addition to introducing a restriction site, this 
procedure  also  altered  two  amino  acids,  changing  Asn146~lle  and 
Asn147~Asp (see Fig.  I).  Both mutagenized and wild-type forms were 
cloned into the vector pCD43 directly downstream of the GALIO promoter. 
Since both forms behaved identically in all assays described, only the strain 
The Journal  of Cell  Biology,  Volume  128~ 1995  770 containing the mutagenized form (designated pGAL-SEC13R) is shown. 
pCIM3  is  a  modified pRS316  (ARS CEN  URA3)  vector (Sikorski  and 
Hieter, 1989) in which divergent GAL/and GALIO promoters have been in- 
troduced between the BamHI and EcoRI sites in the polylinker. The NH2- 
terminal Secl3p/COOH-terminal SECI3Rp chimera was constructed by 
linking a BamHl/Clal SEC13 5' fragment with a ClaI-HindlII SEC13R 3' 
fragment. The reciprocal chimera was constructed by linking a 5' EcoRI- 
ClaI SEC13R fragment with a ClaI-KpnI SEC13 fragment. The SEC13 plas- 
mid was generated by first introducing a BamHI site immediately 5' to the 
initial ATG by PCR, using pCKI313 as a template (Pryer et al., 1993) and 
5'-GCGGATCCAACCATGGTCGTCATAGCTAATGC-Y  as  the  (sense) 
primer. The resulting BamHI/Sacl fragment was cloned into pCD43, and 
was able to rescue see13-1 mutants at the restrictive temperature. 
Chimera Complementation/lnhibition Assays 
All constructs were transformed into RHY305.  The vector pRS315  (Sikor- 
ski and Hieter, 1989) was co-transformed in all experiments, rendering all 
strains effectively prototrophic. Transformants were then assayed at 36°C 
(complementation) or  at  24°C  (inhibition) on synthetic minimal  media 
(Difco Laboratories, Inc., Detroit, MI) supplemented with either 2% glu- 
cose or 2% galactose. 
Radiolabeling and Immunoprecipitations 
Cells  were pre-grown at  24°C  in selective SC  medium containing 2% 
raffinose, and were induced by the addition of 2 % galactose 3 h prior to 
the start of labeling.  1 h before labeling, cells were shifted to 36°C. 8  x 
l07 exponentially growing cells (40D600 units) were radiolabeled in sup- 
plemented SD  medium by  incubating  with  30  #Ci[35S]methionine per 
OI)60o unit (express protein labeling mix [NEN,  Boston,  MA],  sp. act. 
1,200 Ci/mmol). Samples were chased by the addition of 1/100 vol of a solu- 
tion containing 0.1 M ammonium sulfate, 0.3 % cysteine, 0.4 % methionlne. 
Labeled samples of 10Dtoo unit of cells were collected into chilled tubes 
containing 1 vol of 40 mM sodium azide. Protein extracts were prepared 
in 30 ~tl ESB by vigorous agitation with glass beads. Extracts were diluted 
with  I  ml IP buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaC1,  1% Triton 
X-100, 0.2%  SDS), absorbed for 20 min with 50 ~tl  10% Staphylococcus 
aureus cells (Sigma Chemical Co.), and cleared by centrifugation at 12,000 g 
for 5 rain. 0.5 #1 anti-CPY antibody was added, and extracts were rotated 
for 1 h at room temperature. Immune complexes were collected by adding 
25/~1 50% protein A/Sepharose (Pharmacia, Piscataway,  NJ) per sample, 
and incubating an additional hour at room temperature. Protein A/Sepha- 
rose pellets were washed twice with IP buffer, and twice with detergent-free 
IP buffer (50 mM Tris-Cl, pH 7.5,  150 mM NaCI).  Protein was released 
into 30/~I ESB by heating to 100°C for 2 min. 12 td of the supernatant were 
separated  by  SDS-PAGE  and  visualized  by  fluorography  (Harlow  and 
Lane,  1989). 
Generation of  SEC13-deletion Strain 
RHY297  (MATt~ secl3-AI  urn3-52  leu2-3,112 are2-101  ade3-24  [pKR4 
(ARS CEN LEU2 ADE3 SEC13)]) carries a secl3 allele (secl3-A1) in which 
the entire SECI3 coding sequence is deleted. RHY297 was constructed by 
R. Hammer as follows. A 50-nucleotide oligomer (SEC13-NI: Y-CAT TTT 
AAA TTC  TTG  ATA CTC TTC ACG GAT CCG TAT GCT GAT ATA 
AAA TTA TCT GTT ATC-33  consisting of 28 and 26 nucleotides com- 
plementary to the 5' and 3' untranslated region of SECI3,  respectively, and 
six nucleotides creating a BamHI site (underlined) was used to mutagenize 
pKRI (CENSEC13 URA3) (Roberg, K., unpublished results) using the pro- 
tocol of Kunkel et al. (1987).  pRHI02 is a mutagenesis product that lacks 
the entire SEC13 coding region as judged by restriction mapping, but retains 
SEC13 flanking DNA. A 5-kb hisG-URA3-hisG  marker cassette (modified 
from Alani et al., 1987; Elledge, S., unpublished results) was inserted into 
the BamHI site of pRHI02 to make pRH104.  The 6-kb EcoRI-SacI frag- 
ment of pRH104 was transformed into KRY5p4 (MATer secl3-1  urn3-52 
1eu2-3,112 ade2401  ade3-24  [pKR4  (ARS CEN LEU2  ADE3  SECI3)]) 
(Roberg, K., unpublished results). Ura+ transformants that are unable to 
sector at 24°C were selected. RHY297 is a non-sectoring, Ura- derivative, 
selected by plating transformants on medium containing 5-fluoro-orotic acid 
(Boeke et al.,  1984). 
The chimera-suppressed  SEC13-deletion strain was obtained by transfor- 
mation  of  RHY297  using  the  construct  encoding  the. NH2-terminal 
Sec13p/COOH-terminal  SEC13Rp  chimera,  described above,  and  then 
isolating white (pKR4-) colonies. 
Generation of  Antibodies to the SEC13Rp Protein 
SEC13Rp antiserum was elicited against a hybrid protein composed of the 
entire SEC13R coding region fused to Staphyloccocal protein A, using the 
pR/T33 vector (Nilsson and Abrahmsen, 1990).  Hybrid protein was pre- 
pared from Escherichia-coli  extracts and antibody to this protein produced 
in rabbits,  as described previously (Griff et al.,  1992).  Antiserum was 
affinity-purified using  a  ~-galactosidase-SEC13Rp hybrid  protein  con- 
structed by fusing the entire coding sequence of SEC13R to the lacZ gene 
in the pEX2 vector (Stanley and Luzio, 1984).  The hybrid protein was iso- 
lated and used for affinity purification of the antibody as described (Pryer 
et  al.,  1993).  The  affinity-purified anti-sera  was  concentrated using  a 
Centricon-30 microconcentrator (Amicon Corp.). 
Immunofluorescence 
cos  cells or CHO cells were grown in complete medium on 12 mm glass 
coverslips for 2 d prior to recovery. Cells were fixed in 2 % paraformalde- 
hyde,  and  permeabilized in  0.1%  Triton  X-100,  0.02%  SDS.  Affinity- 
purified anti-SEC13Rp was used at a dilution of 1:50 in PBS/10%  FBS in 
the presence of 0.2% saponin; secondary antibody (FITC-conjngated goat 
anti-rabbit;  Boehringer-Mannheim Biochemicals, Indianapolis, IN)  was 
added at a concentration of 1:250, using the same buffer composition. Cov- 
erslips were viewed by epifluorescenee with a Zeiss Axioskop. 
lmmunoelectronmicroscopy 
Rat pancreatic acinar tissue and isolated islets of Langerhans fixed in 1%, 
phosphate-buffered glutaraldehyde  were  processed  for  cryoultramicry- 
otomy according to Tokuyasu (1986).  SECI3Rp was localized by the protein 
A-gold method (Roth et al., 1978). Antibody dilution =  1.50; gold particle 
size =  10 nm. After immunolabeling, the cryosections were stained with 
uranyl acetate. Brefeldin A (BFA) treatment of insulin cells was performed 
as previously described (Orci et al.,  1993a). 
Results 
Complementation of  secl3-1 Defect 
by Human~Yeast Chimeras 
The high degree of sequence similarity between Sec13p and 
SEC13Rp (Fig.  1), distributed along the length of the two 
proteins, encouraged us to ask whether SEC13R could func- 
Human  SECI3Rp  i MVSVINTVDTSHEE01IHDAQMD~YGTRLATCSSDRSVKIFDVRNGGQILI  50 
II  ;  I  I::=1111  :1111  IIIIIII1:  :111:1  :  :  II 
Yeast  Sec13p  1 M~IAN  ....  AHNELIHDAVLDYYGKRLATCSSDKTIKIFEVEGETHKLI  46 
51 VDLRGHEGPVWQVAWAHPMY~ILASCSYDRKVIIWREENGTWEKSHEHA  100 
I  IIIilll  I  IIII  :1  IIIIIIII  I1:11:1111  I  II 
47  DTLTGHEGPVWR%q3WAHPKFGTILASCSYDGKVLIWEEENGRWSQIAVHA  96 
i01  GHDSSVNSVCWAPHDYGLILACGSSDGAISLLTYTGEG~INN~T  150 
I  Illll  Illl;ll  ;I  :1111  :1;:  :  ::1  I  ;11 
97  VHSAS~IqSVQWAPHEYGPLLLVASSDGKVSVVEFKENGT.TSPIIIDAHA  145 
^^ 
151  IGCNAVSWAPAVVPGSLIDHPSGQKPNYIKRFASGGCDNLIKLWKEEEDG  200 
II  I  IIIII  :  :  ;  I  I  :;I  II  III;I;ll  :  I; 
146  IGVNSASW&PATIEED..GE}~GTXES..RKFVTGGADNLVKIWK~/lqSDA  191 
201  Q.WKEEQKLEAHSDW~DVAWAPSIGLPTSTIASCSQDGRVFIWTCDDAS  249 
I  ;  I  I1:1111111111  I  ;  I  I  ;tl  III  ;111  ;I 
192  QTYVLESTLEGHSDWVRDVAWSpTVLLR.SYLASVSQDRTCIIWT.QDNE  239 
250  SNTWSPKLL..HKFNDVVW~SWSITANILAVSGGDNKVTLWKESVDOQW  297 
I  II  If  I1:1:  Ill;  :l:ll;llllltllllll  ;;I  I 
240  QGPWKKTLLKEEKFPDVLWRAS_WSLSGNgLALSGGDNKVTLWKENLEGKW  289 
298  VCISDVNK  305 
;:l: 
290  EPAGEVHQ  297 
Figure  1.  Sequence  comparison  of  yeast  Secl3p  and  human 
SECI3Rp. Identities are indicated by solid lines, similarities are in- 
dicated by dotted lines.  The tv~ amino acids altered during site- 
directed mutagenesis, corresponding to the junction site for chi- 
mera construction (see Materials and Methods), are indicated by 
carats. The Secl3p amino acids altered in the three known SEC13 
temperature-sensitive alleles (see13-1,  see13- 4, sec13-5) are under- 
lined (Pryer et al.,  1993). 
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Figure  2.  Effect  of human/ 
yeast  chimeras  in  a  sec134 
mutant  strain.  (a)  Chimeras 
between human SEC13R and 
yeast SEC13 can complement 
a  secl3-1 temperature-sensi- 
tive allele at the non-permis- 
sive  temperature  (36°C). 
SEC13R, SEC13, or chimeric 
constructs  were  fused  to  a 
galactose-inducible promoter 
in a centromeric vector, trans- 
formed into a sec13-1 mutant, 
and assayed for growth in the 
presence of galactose (induced) 
or glucose (uninduced) at non- 
permissive conditions (36°C). 
(b)  SEC13Rp overexpression 
inhibits the growth of a sec134 
strain.  Assay performed  at 
24°C,  but  otherwise  condi- 
tions identical to a. 
tionally substitute for a defective SEC13 gene. The sec13-1 
allele represents a single point mutation in SEC13,  and can- 
not support growth at temperatures above 30°C (Pryer et al., 
1993). The overexpression of SEC13R cDNA from a galac- 
tose-inducible promoter in a see13-1  strain did not restore 
viability at 36°C (Fig. 2 a). However, significant growth was 
observed at 36°C upon the galactose-induced overexpression 
of a chimeric construct encoding the NH2-terminal half of 
yeast  Secl3p  and  the  COOH-terminal  half  of  human 
SEC13Rp. This chimera was constructed by first creating a 
ClaI restriction site at nucleotide 449 of the human eDNA, 
corresponding to a naturally occurring ClaI site in nueleo- 
tide 488 of the yeast gene; each ClaI site occurs roughly in 
the  middle  of  the  protein  coding  sequence.  The  NH2- 
terminal-encoding half of yeast SEC13 was then fused to the 
COOH-terminal-encoding half of human SEC13R, using the 
ClaI site as a junction (Fig.  1). Induction of a construct en- 
coding only the NH2-terminal half of yeast Secl  3p was un- 
able to complement a sec13-1 defect (data not shown; Pryer 
et al.,  1993), suggesting that the COOH-terminal region of 
Secl3p is functionally required, and is not dispensable (see 
Discussion).  The galactose-induced overexpression of the 
reciprocal chimeric construct,  encoding the NH2-terminal 
half of human  SEC13Rp  and  the COOH-terminal  half of 
yeast Secl3p, also complemented the sec13-1 defect, though 
somewhat less efficiently (Fig. 2 a). 
To demonstrate that both chimeras correct the see13 secre- 
tion defect, the transport of  the marker protein carboxypepti- 
dase Y (CPY) was monitored by pulse-chase analysis. CPY 
is targeted to the vacuole via the ER and Golgi. The core- 
glycosylated pl form of the enzyme can be resolved from the 
form that has received Golgi-specific modification (.p2) and 
the mature form (M) that has been proteolytically cleaved in 
the vacuole (Stevens et al.,  1982). Cells were grown in ex- 
ponential phase at 24°C in medium containing raffinose, in- 
duced for 2 h with galactose, then shifted to 36°C for 1 h. 
Cells were next pulse labeled for 10 min, and then chased 
with excess methionine and cysteine. Lysates were prepared, 
and  immunoprecipitated  with  anti-CPY  antibodies.  In 
sec13-1 mutants, at 36°C, CPY is unable to exit the ER, and 
remains almost exclusively in the pl form (Fig. 3). However, 
upon the galactose-induced overexpression of either the NHz- 
terminal  yeast  Secl3p/COOH-terminal  human  SEC13Rp 
chimera or the NH2-terminal human SEC13Rp/COOH-ter- 
minal yeast Secl3p chimera, CPY is able to exit the ER, pro- 
gress through the Golgi apparatus, and arrive in the vacuole 
(Fig. 3). The observation that either half of SEC13Rp can 
supply sufficient Secl3p activity to permit a  yeast/human 
chimeric protein to complement the temperature-sensitive 
secretion defect of a see13-1 mutant suggests that SEC13Rp 
and Secl3p are functionally similar. 
The ability of SEC13Rp to exhibit Secl3p function was 
illustrated further by the viability of a yeast strain express- 
ing an NH2-terminal yeast Secl3p/COOH-terminal human 
SEC13Rp chimeric protein, but containing no endogenous 
Secl3p (Fig. 4). To determine whether a yeast/human chi- 
Figure 3. Complementation of 
the sec134 secretion defect by 
both  Secl3p/SEC13Rp and 
SEC13Rp/SecI3p  chimeras. 
sec13-1 cells carrying the indi- 
cated  plasmid were  induced 
for 2 h in galactose at 24°C, 
shifted to 36°C for one hour, 
pulse-labeled with Tran35S-label  for 10 min, and then chased by the addition of excess cysteine and methionine. Glass-bead extracts corre- 
sponding to the indicated time points were prepared; immunoprecipitation was performed using anti-CPY antibodies, and the precipitates 
subjected to SDS-PAGE and fluorography. Positions of the pl, p2, and mature forms of CPY are indicated. 
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SEC13Rp chimera. 50/~g  of  protein extract from the indicated  yeast 
strains was analyzed by Western blotting using affinity-purified 
anti-Secl3p antibody,  as described previously (Pryer et al., 1993). 
Lane 1, extracts from wild-type yeast; lane 2, from wild-type yeast 
expressing the Secl3p/SEC13Rp chimera; lane 3, from a SEC13- 
deletion strain expressing the Secl3p/SECI3Rp chimera. 
Figure 5. Specificity  of SECl3Rp-induced growth inhibition. Indi- 
cated yeast strains containing a galactose-inducible  SEC13Rp con- 
struct were incubated at 24°C in the presence of galactose. Strains 
used  were: DSY174  (wild-type), DSY223  (sec12), DSY216 
(secl3), DSY228 (secl6), DSY232 (sec17), and DSY236 (sec18). 
mera could complement a SEC13 deletion, the NH2-termi- 
nal Secl3p/COOH-terminal SEC13Rp construct was trans- 
formed into the indicator strain RHY297.  RHY297  is  an 
ade2-  ade3-  strain in which the entire SEC13 coding se- 
quence has been deleted; the strain carries a plasmid beating 
SEC13, LEU2, and ADE3. The strain is normally dependent 
upon  the  plasmid-encoded  SEC13, and  is  also  colored, 
reflecting the accumulation of a red intermediate resulting 
from ade2-blocked  adenine biosynthesis (Jones and Fink, 
1981; Koshland et al., 1985). However, upon transformation 
with a plasmid capable of complementing the SEC13 dele- 
tion, the SEC13, ADE3, LEU2 plasmid is no longer required, 
and can be lost during colony growth. Plasmid loss is de- 
tected by the appearance of white sectors; in the absence of 
the ADE3 gene product, the adenine biosynthetic pathway is 
blocked at an earlier stage, prior to the ade2 block, and the 
red-colored intermediate is not produced. 
RHY297 was transformed with the construct encoding the 
NH~-terminal Secl3p/COOH-terminal  SEC13Rp  chimeric 
protein, grown on plates containing galactose but not leucine 
(to maintain selection for the LEU2 marker), and analyzed 
by Western.blot using affinity-purified anti-Secl3p antibod- 
ies as a probe (Pryer et al.,  1993).  Yeast Secl3p itself has 
a predicted molecular weight of approximately 33 kD. The 
yeast/human  chimera,  however,  has  a  slightly  heavier 
predicted molecular weight, since the human COOH-termi- 
nal region is 20 amino acids longer than the corresponding 
region of the yeast protein. Extracts from wild-type cells re- 
vealed a  single  band at  33  kD,  representing  endogenous 
Secl3p (Fig. 3).  Extracts from RHY297 ceils transformed 
with  the  yeast/human  chimeric  construct  revealed  two 
bands:  a  33-kD  band representing  Secl3p,  and a  slower- 
migrating band representing the chimeric construct. 
When the RHY297  strain containing the chimeric con- 
struct was then grown on plates containing galactose plus 
rich medium (thus no longer maintaining selection for the 
LEU marker on the SEC13 plasmid), white sectors appeared, 
indicating that in the presence of the chimeric construct, the 
Secl3p-encoding plasmid was no longer necessary. When 
colonies from the white sectors were isolated and analyzed 
by Western blot, a single band appeared at the location ex- 
pected for the chimeric protein (Fig. 4). These data demon- 
strate that the NH2-terminal Secl3p/COOH-terminal SEC- 
13Rp  chimeric protein  can  functionally substitute for an 
absent  Secl3p  protein.  Furthermore,  since  the  chimeric 
product can functionally  replace the endogenous protein, the 
SEC13R-encoded COOH-terminal region must exhibit activ- 
ity similar to that found in the COOH-terminal region of 
Secl3p.  Complementation of a  SEC13 deletion  was  not 
noticeably detected in a yeast strain transformed with the 
reciprocal chimera, a result consistent with the weaker activ- 
ity exhibited by this construct in the suppression of a sec13-1 
growth defect (Fig. 2 a). 
Human SEC13R Specifically Inhibits Growth of a 
sec13-1 Mutant 
In  the  course  of  the  complementation  experiments,  we 
discovered  that  the  galactose-induced  overexpression  of 
SEC13Rp  inhibited the growth of a  sec134  mutant strain 
at permissive temperatures. Although this strain normally 
grows well at 24°C, cell growth was dramatically inhibited 
by the induction of SEC13Rp (Fig. 2 b). Galactose-induced 
overexpression of SEC13Rp produced no evident phenotype 
in  a  wild-type strain or in  strains  carrying temperature- 
sensitive alleles of SEC12, SEC16, SEC17, or SEC18, suggest- 
ing that the observed effect was specific for the sec13-1 strain 
(Fig.  5).  Overexpression  of  the  chimera  encoding  the 
NH2-terminal  half of SEC13Rp  and  the  COOH-terminal 
half of Secl3p also inhibited growth of the sec13-1 strain at 
24°C  (Fig.  2  b),  implying that the NH2-terminal  half of 
SEC13Rp was responsible for this growth inhibition. Con- 
sistent with this interpretation, the NH2-terminal Secl3p/ 
COOH-terminal  SEC13Rp  chimera produced  no  obvious 
phenotype at 24°C.  The inhibitory effect of SEC13Rp ex- 
pression on the growth of a sec13-1 strain at 24°C suggests 
that both SEC13Rp and Secl3-1p may interact with the same 
protein or substrate, and thus may participate in the same 
step or pathway.  For example, SEC13Rp may titrate out a 
Secl3p target by binding to it unproductively. 
Subcellular Localization of SEC13Rp 
To explore further the function of SEC13Rp in mammalian 
cells,  we raised rabbit  serum against a  hybrid protein of 
Staphylococcus protein A fused to SEC13Rp. Antibodies spe- 
cific for SEC13Rp were affinity-purified  using a hybrid pro- 
tein composed ofE. coli/3-galactosidase fused to SECI3Rp. 
Purified antibodies recognized a single prominent band with 
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tisera to the Secl3Rp protein. 
50/~g of the indicated cell ex- 
tracts were subjected to West- 
ern analysis and probed using 
the  affinity-purified  anti- 
SEC13Rp antibody. Lane  1, 
wild-type yeast; lane 2, wild- 
type yeast  +pGAL-SEC13Rp; 
lane  3,  CHO  cells;  lane  4; 
COS ceils. The anti-SEC13Rp 
antibody recognizes a  single 
predominant  species  of  the 
predicted  molecular  weight, 
36 kD. 
the expected molecular weight of approximately 36 kD on 
immunoblots of lysates from wild-type yeast overexpressing 
SEC13Rp or from CHO or COS ceils (Fig. 6). Immunoblots 
of wild-type yeast  lysates  did  not  show  any  pronounced 
bands; this shows that the affinity-purified  anti-SEC13Rp an- 
tibodies do not cross-react with the yeast Secl3p protein. 
The affinity-purified antibody was used to determine the 
subcellular  localization  of SEC13Rp.  By  indirect  immu- 
nofluorescence, SEC13Rp exhibited a "diamond ring" appear- 
ance,  encircling the nucleus in both CHO and COS  cells 
(Fig. 7, a and b). To determine more precisely the subcellular 
distribution of SEC13Rp, we used immunoelectronmicros- 
copy, and  focused on two cell types  with well-developed 
secretory compartments, the insulin and the acinar cells of 
the pancreas (Fig.  8, a  and b). In both of these cell types, 
SEC13Rp was found concentrated in the transitional area of 
the ER (Table I), in a distribution indistinguishable from that 
previously observed for mammalian Sec23p in the same cells 
(Orci et ai., 1991). Furthermore, as previously observed for 
mammalian Sec23p (Orci et ai.,  1993a), the distribution of 
SEC13Rp was not altered by brefeldin A treatment, and re- 
mained excluded from coatomer-rich areas of "BFA bodies" 
(Fig. 9). These data are consistent with the view that SEC- 
13Rp and  mammalian  Sec23p are not constituents of the 
coatomer,  but rather  are both  components of a  different 
structure (most likely, mammalian COPII) involved in ER to 
Golgi transport. 
Discussion 
This report provides strong evidence that the function of 
Secl3p  has  been  highly  conserved through  evolution.  In 
yeast, Secl3p is required for vesicle budding from the ER, 
and has been identified as a constituent of the vesicle-coating 
protein  complex  designated  COPII  (Pryer  et  al.,  1993; 
Barlowe et al., 1994). We have shown that two reciprocal hu- 
man/yeast chimeric Secl3 constructs can each complement 
a sec13-1 mutant, and can rescue both the growth defect and 
the secretion defect. We have also shown that one of these 
chimeric constructs can complement a deletion of SEC13. In 
addition,  we have demonstrated that the human SEC13Rp 
protein itself inhibits the growth of a Sec13-1 mutant, but not 
of  either  wild-type  yeast  or  mutants  in  SEC12, SEC16, 
SEC17, or SEC18. We also show that SEC13Rp is located in 
Figure  7.  Localization  of  SEC13Rp by  immunofluorescence. 
SEC13Rp appears in a perinuclear distribution in (a) CHO and (b) 
COS cells. Immunofluorescence performed using afffinity-purified 
anti-SEC13Rp antibodies. Magnification:  x'/00. 
the transitional ER, in a distribution identical to that previ- 
ously observed for mammalian Sec23. Finally, we show that 
the cellular distribution of SEC13Rp is insensitive to BFA 
treatment, consistent with the behavior previously observed 
for mammalian Sec23, but not for coatomer components. 
Complementation of the growth defect of a sec13-1 mu- 
tant at 36°C  represents a  stringent assay that requires no 
presumptions  about  the  specific function of Secl3p.  The 
ability of both yeast/human chimeric proteins to comple- 
ment a sec13-1 mutant implies that in both cases, the human 
region of the chimeric protein is fulfilling the function or 
functions normally performed by the corresponding region 
of the yeast protein. The ability of both chimeras to restore 
CPY transport in a sec13-1 strain specifically demonstrates 
complementation of the ER to Golgi secretion defect charac- 
teristic of sec13-1 mutants. 
If  the  two  reciprocal  chimeras  complement  both  the 
growth defect and the secretion defect of a sec13-1 mutant, 
then why does the entire SEC13R cDNA not complement ei- 
ther defect? We believe that there are at least two contribut- 
ing factors. First, we would suggest that although both halves 
of human SEC13Rp can function in yeast, they do not func- 
tion at quite the same level of wild-type Secl3p; this would 
explain why the full-length SECI3Rp protein, representing 
the sum of two sub-optimal halves, cannot rescue the sec13-1 
secretion defect. Second, we would propose that in a sec13-1 
strain,  the NH2-terminai region of SEC13Rp is  toxic, re- 
suiting  in  the  growth  defect observed at  24°C  in  strains 
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scope  immunolabeling of (a) 
insulin or (b) acinar rat pan- 
creatic cells,  SEC13Rp  is re- 
stricted to the transitional area 
of  the  ER.  Transitional  ele- 
ments (TE) of the ER with as- 
sociated  transfer  vesicles 
(asterisks); the  arrow  in  the 
inset indicates a  labeled  bud 
on a  transitional cisterna;  G, 
Golgi complex;  CV, condens- 
ing  vacuole  in the Golgi  re- 
gion.  Note  that  the  dense 
cytosolic matrix in the transi- 
tional area of b is also labeled 
in  addition  to  transfer  vesi- 
cles. See Table I for the quan- 
titation  of  the  immunogold 
labeling.  Magnifications:  (a) 
x53,000  (inset,  x72,000); 
(b)  x54,000.  Bars: (a and b) 
0.5 #m;  (inset) 0.1  #m. 
Table L  SEC13Rp Immunogoid Labeling of Transitional Area,  ER,  and Golgi of Pancreatic Acinar and Insulin  Cells 
Number of gold particles per/~m  2 ±  SEM 
Acinar cell  Insulin cell 
ER (n  =  10)  0.34  0.18 
Transitional  61  ±  13  110  +  23 
area* (n  =  10) 
(54  :t:  6  vesicles per/zm2; 28%  +  4%  (105  +  15 vesicles per #m2; 48%  ±  7% 
of vesicles labeled)  of vesicles labeled) 
Golgi (n  ---  10)  1 +  0.7  2  ±  1 
n, number of pictures evaluated. Quantitation was performed as described previously (Orci et al.,  1991). 
* Including the budding front of the transitional ER, vesicles, and intervening eytosol. 
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are present on the buds (arrows) and vesicles associated with the 
transitional endoplasmic reticulum cisterna (TE), but are absent 
from the dense bands of cytosol (arrowheads) enriched in coatomer 
(Orci  et  al.,  1993a), situated  between  transitional  and  non- 
transitional ER cisternae. BFA-treated insulin cell. Magnification: 
x47,600. Bar, 0.5 t~m. 
expressing either the  full-length SEC13Rp  protein or the 
NH2-terminal  SEC13Rp/COOH-terminal  Secl3p  protein. 
Although the precise reason for this toxicity is not known, 
the observation that it is only seen in a sec13 mutant, and not 
in either a wild-type strain or in other sec mutants, suggests 
a  synthetic lethal interaction between SEC13R and sec13-1, 
and implies that secl3-1p and SEC13Rp participate in the 
same pathway,  and perhaps compete for a common target. 
The ability of the NH2-terminal SEC13Rp/COOH-terminal 
Secl3p protein to rescue a sec13-1  secretion defect at 36°C 
suggests that the toxicity associated with the NH2-terminal 
region of SEC13Rp develops over a period of time longer 
than that encompassed by the pulse-chase assay. 
Localization of SEC13Rp to the transitional ER and asso- 
ciated transport vesicles represents an important observa- 
tion. These data not only situate SEC13Rp in precisely the 
area expected for a mammalian protein involved in ER to 
Golgi transport, but also emphasize that SEC13Rp is con- 
centrated at this level. This is strong evidence that SEC13Rp 
is specifically involved in ER to Golgi transport. If SEC13Rp 
is in fact a component of a mammalian COPII complex, then 
these data would suggest that COPII is involved solely in 
transport between the ER and the Golgi apparatus, and, un- 
like coatomer, is not involved in intra-Golgi transport. 
The observation that SEC13Rp does not redistribute upon 
BFA treatment is encouraging because it places SEC13Rp 
and mammalian Sec23p in a different category from all the 
known coatomer components.  Furthermore,  since BFA is 
known to inhibit the binding of ARF to donor membranes, 
it is tempting to speculate that ARF is not involved in the 
recruitment of SEC13Rp and mammalian Sec23p; perhaps 
this function is fulfilled by Sarl. 
Functional complementation of a yeast mutant by a  hu- 
man/yeast chimera has been reported for a number of differ- 
ent genes. Mutants in yeast genes encoding the transcription 
factor SWI2p (Khavari et al., 1993), the nucleotide exchange 
factor CDC25p (Wei et al., 1992), the RNA-binding protein 
SNPlp (Smith and Barrell, 1991), and the ABC-transporter 
STE6p (Teem et al.,  1993) have all been complemented by 
chimeric constructs consisting of fused regions of the wild- 
type yeast gene and its putative mammalian homologue. Not 
only does such complementation demonstrate the conserva- 
tion of function between yeast and human gene products, but 
it can also allow for the detailed study of  the mammalian pro- 
tein, as is illustrated by the work by Teem et al., (1993) on 
the cystic fibrosis transmembrane conductance regulator. 
Together, the data presented in this report argue that the 
function of Secl3p has been conserved from yeast to hu- 
mans, and also support the existence of a mammalian COPII 
complex.  More generally, our results emphasize that chi- 
mera studies represent a useful, easily-adaptable approach 
for applying the tools of yeast genetics to the study of con- 
served mammalian proteins. 
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